2016-03-08T00:00:00.000-05:00
diverse platform technologies,0.412319
technology platforms,0.558567
pancreatic cancer,-0.504201
proprietary attenuated strains,-0.673803
related personnel expenses,0.207391
compelling clinical data,0.357371
ongoing trials,-0.504201
clinical product candidates,0.207391
Novartis agreements,0.518463
development expenses,-0.504201
infectious diseases,-0.621979
advanced cancers,0.357371
upfront fees,0.518463
global pharmaceutical companies,0.753123
GLOBE NEWSWIRE,0.239
LADD technology platform,-0.673803
lead indication,-0.504201
continued workforce growth,0.207391
cancer indications,-0.635547
net loss,-0.362096
Pathway Activator platform,0.610723
tumor-associated antigens,-0.673803
immunotherapy field,0.412319
tumor-specific immune response,0.681159
deep pipeline,0.412319
intracellular STING receptor,0.610723
fair value,-0.272666
targeted immune responses,-0.673803
Stephen T. Isaacs,0.220572
development-related milestones,0.518463
manufacturing costs,0.207391
clinical development expenses,-0.504201
warrant exercise expired.,-0.318276
tremendous progress,0.412319
initial therapeutic priorities,0.412319
immunotherapy company,0.231821
late stages,0.412319
